Patents Assigned to ES Cell International Pte Ltd
-
Patent number: 11198849Abstract: There is described a method of promoting the attachment, survival and/or proliferation of a stem cell in culture, the method comprising culturing a stem cell on a positively-charged support surface. There are also provided a cell composition prepared according to the method of the invention.Type: GrantFiled: February 25, 2015Date of Patent: December 14, 2021Assignee: ES CELL INTERNATIONAL PTE LTDInventors: Jeremy Micah Crook, Rachel Horne, Blaine Wesley Phillips
-
Patent number: 10760049Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.Type: GrantFiled: May 15, 2017Date of Patent: September 1, 2020Assignee: ES Cell International PTE Ltd.Inventor: Benjamin Eithan Reubinoff
-
Patent number: 10472606Abstract: The present invention provides a method for freezing a stem cell or a cell derived therefrom, the method including the steps of providing a cell suspension, performing ice nucleation on the cell suspension, and lowering the temperature of the ice nucleated cell suspension to a temperature sufficiently low to allow long term storage of the stem cell. The method is preferably used for the cryopreservation of human embryonic stem cells.Type: GrantFiled: June 8, 2017Date of Patent: November 12, 2019Assignee: ES Cell International Pte LtdInventors: Jeremy M. Crook, Lucy Kravets
-
Patent number: 9994822Abstract: This invention provides a method for testing a factor for cardiogenicity which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence and absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and measuring the differentiation in the presence and absence of the factor. This invention also provides a method for identifying a cardiogenic factor, which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and identifying the factor that affects the differentiation of human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor.Type: GrantFiled: August 24, 2015Date of Patent: June 12, 2018Assignee: ES Cell International Pte LtdInventors: Robert Passier, Christine L. Mummery
-
Publication number: 20170335278Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.Type: ApplicationFiled: May 15, 2017Publication date: November 23, 2017Applicant: ES Cell International PTE Ltd.Inventor: Benjamin Eithan REUBINOFF
-
Publication number: 20170275588Abstract: The present invention provides a method for freezing a stem cell or a cell derived therefrom, the method including the steps of providing a cell suspension, performing ice nucleation on the cell suspension, and lowering the temperature of the ice nucleated cell suspension to a temperature sufficiently low to allow long term storage of the stem cell. The method is preferably used for the cryopreservation of human embryonic stem cells.Type: ApplicationFiled: June 8, 2017Publication date: September 28, 2017Applicant: ES CELL INTERNATIONAL PTE LTD.Inventors: Jeremy M Crook, Lucy Kravets
-
Patent number: 9714412Abstract: The present invention provides a method for freezing a stem cell or a cell derived therefrom, the method including the steps of providing a cell suspension, performing ice nucleation on the cell suspension, and lowering the temperature of the ice nucleated cell suspension to a temperature sufficiently low to allow long term storage of the stem cell. The method is preferably used for the cryopreservation of human embryonic stem cells.Type: GrantFiled: June 2, 2005Date of Patent: July 25, 2017Assignee: ES Cell International Pte Ltd.Inventors: Jeremy M Crook, Lucy Kravets
-
Patent number: 9650605Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.Type: GrantFiled: January 30, 2012Date of Patent: May 16, 2017Assignee: ES Cell International PTE Ltd.Inventor: Benjamin Eithan Reubinoff
-
Patent number: 9422521Abstract: The present invention provides a process of differentiating stem cells, in particular hES cells, into cardiomyocytes and into neural progenitors by growing the hES cells in the presence of a defined medium that is substantially free of xeno- and serum-components and thus comprises a clinically compliant medium. The defined media comprises defined factors that contribute to the promotion of differentiation to cardiomyocytes and neural progenitors. The invention also includes defined culture media and cell populations and methods of using them.Type: GrantFiled: September 12, 2006Date of Patent: August 23, 2016Assignee: ES Cell International Pte Ltd.Inventors: Bruce Paul Davidson, Ralph Eberard Graichen, Robert Zweigerdt, Xiuqin Xu
-
Patent number: 9404085Abstract: The present invention relates to the induction of differentiation in human embryonic stem (hES) cells to cardiomyocytes and factors such as prostaglandin I2 (PGI2), Fgf 9, Bmp6, Bmp4, Scf, Igf2, and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from hES cells is also provided wherein the media contains these factors. Genes that are upregulated in the process of cardiomyocyte differentiation are also provided.Type: GrantFiled: October 12, 2012Date of Patent: August 2, 2016Assignee: ES Cell International PTE LTD.Inventors: Bruce Paul Davidson, Ralph Eberhard Graichen, Robert Zweigerdt, Xiuqin Xu, Christine Lindsay Mummery, William Sun
-
Patent number: 9080147Abstract: The present invention provides a preparation of undifferentiated embryonic stem (ES) cells sustainable for a prolonged period in an undifferentiated state which will undergo stem cell renewal or somatic differentiation. Preferably the cells are capable of somatic differentiation in vitro and are inclined to differentiate away from an extraembryonic lineage. The present invention also provides method of culturing embryonic stem (ES) cells to improve stem cell maintenance and persistence in culture. The method also provides a culture of ES cells prepared by the method as well as differentiated cells derived from the embryonic cells resulting from directed differentiation procedures provided by the present invention.Type: GrantFiled: January 30, 2009Date of Patent: July 14, 2015Assignee: ES Cell International PTE Ltd.Inventor: Martin Frederick Pera
-
Publication number: 20140287495Abstract: The present invention relates to methods of inducing differentiation of stem cells. In particular, the invention relates to methods of inducing differentiation of embryonic stem cells into muscle cells or vascular endothelial cells. The invention also includes cells, cell lines, testing models and culture systems used in the methods of the present invention and differentiated cells produced therefrom. The present invention also provides methods of using the differentiated cells of the present invention for therapeutic purposes.Type: ApplicationFiled: March 25, 2014Publication date: September 25, 2014Applicant: ES Cell International Pte LTDInventor: Christine Lindsay Mummery
-
Publication number: 20140193909Abstract: The present invention relates to the induction of differentiation in human embryonic stem (hES) cells to cardiomyocytes and factors such as prostaglandin I2 (PGI2), Fgf 9, Bmp6, Bmp4, Scf, Igf2, and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from hES cells is also provided wherein the media contains these factors. Genes that are upregulated in the process of cardiomyocyte differentiation are also provided.Type: ApplicationFiled: October 12, 2012Publication date: July 10, 2014Applicant: ES CELL INTERNATIONAL PTE LTDInventors: Bruce Paul Davidson, Ralph Eberhard Graichen, Robert Zweigerdt, Xiuqin Xu, Christine Lindsay Mummery, William Sun
-
Publication number: 20130330821Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: ApplicationFiled: May 1, 2013Publication date: December 12, 2013Applicant: ES CELL INTERNATIONAL PTE LTD.Inventors: BENJAMIN EITHAN REUBINOFF, MARTIN Federick PERA, TAMIR BEN-HUR
-
Patent number: 8460931Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: GrantFiled: January 31, 2012Date of Patent: June 11, 2013Assignee: ES Cell International PTE Ltd.Inventors: Benjamin Eithan Reubinoff, Martin Federick Pera, Tamir Ben-Hur
-
Publication number: 20120178095Abstract: This invention provides a method for testing a factor for cardiogenicity which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence and absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and measuring the differentiation in the presence and absence of the factor. This invention also provides a method for identifying a cardiogenic factor, which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and identifying the factor that affects the differentiation of human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor.Type: ApplicationFiled: March 26, 2012Publication date: July 12, 2012Applicant: ES CELL INTERNATIONAL PTE LTDInventors: Robert Passier, Christine Lindsay Mummery
-
Publication number: 20120122109Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: ApplicationFiled: January 31, 2012Publication date: May 17, 2012Applicant: ES Cell International PTE Ltd.Inventors: Benjamin Eithan REUBINOFF, Martin Federick Pera, Tamir Ben-Hur
-
Publication number: 20120122211Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.Type: ApplicationFiled: January 30, 2012Publication date: May 17, 2012Applicant: ES Cell International PTE Ltd.Inventor: Benjamin Eithan REUBINOFF
-
Publication number: 20120115229Abstract: The present invention provides undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, and committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. The invention also provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and the cells that are generated along the pathway of neural differentiation may be used for the study of the cellular and molecular biology of human neural development, for the discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, for drug discovery and for the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: ApplicationFiled: April 28, 2011Publication date: May 10, 2012Applicant: ES CELL INTERNATIONAL PTE LTD.Inventors: BENJAMIN EITHAN REUBINOFF, MARTIN FREDERICK PERA, TAMIR BEN-HUR
-
Patent number: 8158421Abstract: The present invention provides a method of enhancing the efficiency of differentiation of hES cells into cardiomyocytes which method comprises incubating the cells under serum free conditions. The method typically includes providing cells that induce cardiomyocyte differentiation by cell to cell contact. Differentiation to cardiomyocytes can occur via two routes, namely by spontaneous differentiation and by induced differentiation. Without wishing to be bound by theory the present inventors hypothesize that, in the case of induced differentiation, END-2 cells, for instance, are needed for aggregation to cause local high cell densities and in inducing differentiation of nascent mesoderm. This second step could be enhanced in any human embryonic stem cell line leading to the prediction that it will work in lines other than hES. In cell lines that undergo spontaneous differentiation, it is hypothesized that local induction of embryoid bodies in endoderm occurs.Type: GrantFiled: June 1, 2004Date of Patent: April 17, 2012Assignee: ES Cell International Pte LtdInventors: Robert Passier, Christine Lindsay Mummery